Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
The NDA filing is supported by results from the phase III evERA Breast Cancer study
Each company will share operational data with Evinova, feeding the platform’s AI engines to provide benchmarks and actionable insights, aiming to speed up trials while maintaining top-tier patient care
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
TB Alliance will continue to lead clinical development, while Lupin will leverage its global manufacturing, regulatory, and supply chain expertise to ensure the drug reaches patients worldwide
The pioneering monoclonal antibody is for Essential Thrombocythemia (ET) and Polycythemia Vera (PV), rare chronic blood cancers with limited treatment options
Subscribe To Our Newsletter & Stay Updated
